Showing results (161-170 of 181) with videos related to
Sort By:
Pageof 19
International Journal of Cancer|February 2, 2013
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER studyC A Drukker, J M Bueno-de-Mesquita, V P Retèl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancerG C de Gast, F A Vyth-Dreese, W Nooijen, et al.Cancer Chemotherapy and Pharmacology|January 1, 1996
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedureL J van Warmerdam, G J Creemers, S Rodenhuis, et al.Breast Cancer Research and Treatment|July 27, 2015
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measureM Jebbink, E van Werkhoven, I A M Mandjes, et al.Anticancer Research|September 1, 1996
Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumoursJ W Baars, M J Holtkamp, W J Nooyen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantationM W Dercksen, S Rodenhuis, M K Dirkson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trialA Le Cesne, J Y Blay, I Judson, et al.Familial Cancer|February 22, 2015
Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON studyM R Wevers, M K Schmidt, E G Engelhardt, et al.European Journal of Nuclear Medicine and Molecular Imaging|August 17, 2012
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapyB B Koolen, M J T F D Vrancken Peeters, J Wesseling, et al.Nederlands Tijdschrift Voor Geneeskunde|December 6, 2008
[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]M E Straver, J C van Adrichem, E J Th Rutgers, et al.Pageof 19